EndoQuest, a company specializing in endoluminal robotics technology, has successfully closed a $42 million C-1 preferred financing round. This round saw participation from existing investors CE Ventures Limited and McNair Interests Ltd., as well as new investor Puma Venture Capital LLC. Based in Houston, EndoQuest has developed a flexible robotics surgery system designed for minimally invasive procedures in the gastrointestinal tract and other endoluminal areas. This technology enables endoluminal and single-incision surgeries through natural body orifices or via a transumbilical incision.
The company plans to use the newly acquired funds to expand its operations, which includes scaling up commercialization efforts, achieving regulatory milestones, and advancing research and development. Kurt Azarbarzin, CEO of EndoQuest Robotics, emphasized the goal of leveraging robotics to revolutionize minimally invasive procedures, enhancing patient care and transforming the future of endoluminal interventions.
EndoQuest’s technology has already been adopted by Brigham and Women’s Hospital in Boston, assisting therapeutic endoscopists and surgeons in performing scar-free upper and lower gastrointestinal surgery. The funding and development of EndoQuest are part of a larger trend in the medical field, where robotics companies are increasingly attracting significant investments. For instance, Mendaera, a California-based company, secured $24 million in Series A funding for its platform that combines real-time imaging, AI, and robotics for precision medicine. Similarly, Diligent Robotics raised $25 million in funding for its autonomous clinical support robot, Moxi, which assists hospital personnel with various tasks.